Jill C. Milne - 23 Jan 2026 Form 4 Insider Report for BIOCRYST PHARMACEUTICALS INC (BCRX)

Role: Director
Signature: /s/ Alane P. Barnes, by power of attorney
Issuer symbol: BCRX
Transactions as of: 23 Jan 2026
Net transactions value: $0
Form type: 4
Filing time: 27 Jan 2026, 17:22:33 UTC
Previous filing: 25 Mar 2025
Next filing: 03 Mar 2026
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Milne Jill C.	Director	4505 EMPEROR BLVD, SUITE 200, DURHAM	/s/ Alane P. Barnes, by power of attorney	27 Jan 2026	0001644246

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	BCRX	Common Stock	Award		+2,582			2,582	23 Jan 2026	Direct	F1
transaction	BCRX	Common Stock	Award	$0	+12,272	+475%	$0.000000	14,854	23 Jan 2026	Direct	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	BCRX	Automatic Stock Option Grant	Award	$0	+26,684		$0.000000	26,684	23 Jan 2026	Common Stock	26,684	$6.79	Direct	F3, F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Received in exchange for 4,377 shares of Astria Therapeutics, Inc. ("Astria") common stock in connection with a merger (the "Merger"), pursuant to which Astria became a wholly owned subsidiary of BioCryst Pharmaceuticals, Inc. ("BioCryst"). Pursuant to the Merger, each share of Astria common stock (subject to certain inapplicable exceptions) was converted into the right to receive (i) 0.59 of a share of common stock of BioCryst and, if applicable, cash in lieu of fractional shares, and (ii) $8.55 in cash, without interest, subject to applicable withholding taxes. On the last trading day before the effective date of the Merger, the closing price of Astria's common stock was $12.58 per share, and the closing price of BioCryst's common stock was $6.75 per share.
F2	Automatic non-employee director grant of restricted stock units pursuant to the BioCryst Non-Employee Director Compensation Policy, as amended (the "Director Compensation Policy"), which will vest in three equal annual installments beginning on the twelve-month anniversary of the date of grant.
F3	Automatic non-employee director grant of stock options pursuant to the Director Compensation Policy.
F4	The option grant vests 1/36 per month over a 3-year period measured from the date of grant.